C-reactive protein as a possible marker for severity and mortality of COVID-19 infection
Gastroenterology and Hepatology from Bed to Bench,
Vol. 14 No. Supplement 1 (2021),
30 December 2021
https://doi.org/10.22037/ghfbb.vi.2388
Abstract
Aim: The present study aimed to introduce a possible biomarker to differentiate between severe and fatal conditions of COVID-19.
Background: The COVID-19 pandemic, appearing as a complicated health problem, has changed the lifestyle of people in recent years. Clinical findings indicate mild, severe, and fatal conditions of this disease. Prediction of disease severity is a significant point in managing COVID-19 infection
Methods: In this study, 195 differentially expressed genes (DEGs) that discriminate between fatal and severe conditions in patients were extracted from the literature and screened to determine the significant ones. The significant DEGs plus the 90 first neighbors added from the STRING database were included in the interactome using Cytoscape software v 3.7.2. The central nodes of the analyzed network were identified and assessed.
Results: Ten significant DEGs were candidates for assessment, of which 9 were recognized by the STRING database. IL6, ALB, TNF, CRP, INS, MPO, C3, CXCL8, TTR, and TLR4 were determined as central nodes; IL6, CRP, and TTR were highlighted as the critical genes related to the severity of COVID-19 infection.
Conclusion: CRP was identified as the best possible biomarker with levels related to the severity and fatality of COVID-19 infection.
- C-reactive protein; COVID-19; Bioinformatics; Severity; Network analysis
How to Cite
References
2. Pietromonaco PR, Overall NC. Applying relationship science to evaluate how the COVID-19 pandemic may impact couples’ relationships. American Psychologist. 2020.
3. Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir–a potential treatment in the COVID-19 pandemic? Journal of virus eradication. 2020;6(2):45-51.
4. Obi AT, Barnes GD, Wakefield TW, Brown S, Eliason JL, Arndt E, et al. Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 pandemic. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2020;8(4):526-34.
5. Cirrincione L, Plescia F, Ledda C, Rapisarda V, Martorana D, Moldovan RE, et al. COVID-19 pandemic: prevention and protection measures to be adopted at the workplace. Sustainability. 2020;12(9):3603.
6. Zhang Y, Ren J. ALDH2 in alcoholic heart diseases: molecular mechanism and clinical implications. Pharmacology & therapeutics. 2011;132(1):86-95.
7. Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World journal of gastroenterology. 2016;22(42):9300.
8. Churko JM, Mantalas GL, Snyder MP, Wu JC. Overview of high throughput sequencing technologies to elucidate molecular pathways in cardiovascular diseases. Circulation research. 2013;112(12):1613-23.
9. Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nature medicine. 2004;10(11):1177-85.
10. Barbosa EB, Vidotto A, Polachini GM, Henrique T, Marqui ABTd, Tajara EH. Proteomics: methodologies and applications to the study of human diseases. Revista da Associacao Medica Brasileira. 2012;58(3):366-75.
11. Guingab-Cagmat J, Cagmat E, Hayes RL, Anagli J. Integration of proteomics, bioinformatics, and systems biology in traumatic brain injury biomarker discovery. Frontiers in neurology. 2013;4:61.
12. Wu X, Al Hasan M, Chen JY. Pathway and network analysis in proteomics. Journal of theoretical biology. 2014;362:44-52.
13. Santiago JA, Potashkin JA. Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes. PloS one. 2013;8(12):e83940.
14. Özgür A, Vu T, Erkan G, Radev DR. Identifying gene-disease associations using centrality on a literature mined gene-interaction network. Bioinformatics. 2008;24(13):i277-i85.
15. Sadria M, Karimi S, Layton AT. Network centrality analysis of eye-gaze data in autism spectrum disorder. Computers in biology and medicine. 2019;111:103332.
16. Wang M, Huang J, Liu M, Zhang D, editors. Functional connectivity network analysis with discriminative hub detection for brain disease identification. Proceedings of the AAAI Conference on Artificial Intelligence; 2019.
17. Pavel A, Del Giudice G, Federico A, Di Lieto A, Kinaret PA, Serra A, et al. Integrated network analysis reveals new genes suggesting COVID-19 chronic effects and treatment. Briefings in bioinformatics. 2021;22(2):1430-41.
18. Rezaei-Tavirani M, Nejad MR, Arjmand B, Tavirani SR, Razzaghi M, Mansouri V. Fibrinogen Dysregulation is a Prominent Process in Fatal Conditions of COVID-19 Infection; a Proteomic Analysis. Archives of Academic Emergency Medicine. 2021;9(1):e26-e.
19. Shu T, Ning W, Wu D, Xu J, Han Q, Huang M, et al. Plasma proteomics identify biomarkers and pathogenesis of COVID-19. Immunity. 2020;53(5):1108-22. e5.
20. Wang L. C-reactive protein levels in the early stage of COVID-19. Medecine et maladies infectieuses. 2020;50(4):332-4.
21. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Annals of clinical microbiology and antimicrobials. 2020;19:1-7.
22. Potempa LA, Rajab IM, Hart PC, Bordon J, Fernandez-Botran R. Insights into the use of C-reactive protein as a diagnostic index of disease severity in COVID-19 infections. The American journal of tropical medicine and hygiene. 2020;103(2):561-3.
23. Acar E, Demir A, Yıldırım B, Kaya MG, Gökçek K. The role of hemogram parameters and CRP in predicting mortality in COVID‐19 infection. International journal of clinical practice. 2021:e14256.
24. Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Medecine et maladies infectieuses. 2020.
25. Zhang H, Wang X, Fu Z, Luo M, Zhang Z, Zhang K, et al. Potential factors for prediction of disease severity of COVID-19 patients. MedRxiv. 2020.
26. Lopez-Castaneda S, García-Larragoiti N, Cano-Mendez A, Blancas-Ayala K, Damian-Vázquez G, Perez-Medina AI, et al. Inflammatory and Prothrombotic Biomarkers Associated With the Severity of COVID-19 Infection. Clinical and Applied Thrombosis/Hemostasis. 2021;27:1076029621999099.
27. Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up. Brain, behavior, and immunity. 2021;94:138-47.
28. Vassiliou AG, Keskinidou C, Jahaj E, Gallos P, Dimopoulou I, Kotanidou A, et al. ICU admission levels of endothelial biomarkers as predictors of mortality in critically ill COVID-19 patients. Cells. 2021;10(1):186.
- Abstract Viewed: 51 times
- pdf Downloaded: 34 times